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Abstract
Background: This article provides a summary of the 2013 European Renal Association–European Dialysis and Transplant
Association (ERA-EDTA) Registry Annual Report (available at http://www.era-edta-reg.org), with a focus on patients with
diabetes mellitus (DM) as the cause of end-stage renal disease (ESRD).
Methods: In 2015, the ERA-EDTA Registry received data on renal replacement therapy (RRT) for ESRD from 49 national or
regional renal registries in 34 countries in Europe andbordering theMediterraneanSea. Individual patient datawere provided by
31 registries, while 18 registries provided aggregated data. The total population covered by the participating registries comprised
650 million people.
Results: In total, 72 933 patients started RRT for ESRD within the countries and regions reporting to the ERA-EDTA Registry,
resulting in an overall incidence of 112 permillion population (pmp). The overall prevalence on 31 December 2013was 738 pmp
(n = 478 990). Patients with DM as the cause of ESRD comprised 24% of the incident RRT patients (26 pmp) and 17% of the
prevalent RRTpatients (122 pmp).Whencomparedwith theUSA, the incidenceof patients startingRRTpmpsecondary toDM in
Europe was ﬁve times lower and the incidence of RRT due to other causes of ESRD was two times lower. Overall, 19 426 kidney
transplants were performed (30 pmp). The 5-year adjusted survival for all RRT patients was 60.9% [95% conﬁdence interval (CI)
60.5–61.3] and 50.6% (95% CI 49.9–51.2) for patients with DM as the cause of ESRD.
Key words: end-stage renal disease, incidence, prevalence, renal replacement therapy, survival
Introduction
The European Renal Association–European Dialysis and Trans-
plant Association (ERA-EDTA) Registry collects data on renal
replacement therapy (RRT) for end-stage renal disease (ESRD)
via national and regional renal registries in Europe and from
countries bordering the Mediterranean Sea. Each year an annual
report is produced, presenting an overview of the incidence and
prevalence of RRT, kidney transplant activity and the survival of
patients on RRT in Europe. With this article, we aim to provide a
summary of the 2013 Annual Report of the ERA-EDTARegistry [1].
Both the Annual Report and slides summarizing the Annual
Report are available at http://www.era-edta-reg.org. This article
speciﬁcally focuses on the most common cause of ESRD in the
Western world: diabetes mellitus (DM).
Methods
In 2015, the ERA-EDTA Registry received 2013 data from 49
national and regional renal registries in 34 countries in Europe
and those bordering the Mediterranean Sea. The majority of
renal registries (31 of 49) contributed individual patient data,
whereas the other 18 renal registries contributed aggregated
data (Figure 1).
While a standard Microsoft Excel template was used for the
collection of aggregated data, the individual patient data were
received in different formats, including SPSS, Microsoft Excel
and SAS. Extensive data checking was performed and the data
were converted to a standard format in order to be stored in a
relational database. After data analysis, the results were checked
by the participating renal registries. All registry-speciﬁc results in
the ERA-EDTA Registry Annual Report were approved by the
registries before publication.
Mid-year population data for the contributing countries/
regions were received from Eurostat (http://ec.europa.eu/eurostat),
the national bureau of statistics or the renal registry.
The incidence of RRT was deﬁned as the number of patients
starting RRT in one year (2013) and the prevalence of RRT as
the number of patients alive and receiving RRT on 31 December
2013. Incidence and prevalence per million population (pmp)
were calculated by dividing the observed count by the mid-year
population. Time trends of the incidence rates were analysed
using Joinpoint regression, with the trends presented as annual
percentage change (APC) [2, 3].
Patient survival onRRT, ondialysis and following kidney trans-
plantationwas analysed using data from renal registries providing
individual patient data for the period 2004–13. A detailed descrip-
tion of the survival methods is given in the Appendix.
Patients were included in the DM subgroup if they were
registered as having DM type 1 or type 2 as the cause of ESRD
(ERA-EDTA primary renal disease 1995 codes 80 or 81 or ERA-
EDTA primary renal disease 2012 codes 2316, 2328, 2337 or 2344
Fig. 1. Renal registries from countries and regions in Europe and bordering the
Mediterranean Sea that contributed individual patient data or aggregated data
to the ERA-EDTA Registry for 2013.
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[1]). As information on DM as comorbidity is not routinely col-
lected by the ERA-EDTA Registry, this article only focuses on
DM as the cause of ESRD.
Statistical methods
Within this article, patient survival on RRT and following kidney
transplantation was analysed using the Kaplan–Meier method
and Cox proportional hazards regression. For dialysis patients,
kidney transplantation is an event that competes with death.
Therefore, we used the cumulative incidence competing risk
method for the estimation of the unadjusted cause-speciﬁc
death probabilities, and the Fine and Gray method for the ad-
justed cause-speciﬁc death probabilities [7]. For the calculation
of patient survival on RRT and on dialysis, the date of RRT initi-
ation was the starting point and death was the event studied.
Censored observations were recovery of renal function, loss to
follow-up and end of the follow-up period (31 December 2013).
For analysis of patient survival following kidney transplantation,
the date of the ﬁrst kidney transplant was deﬁned as the ﬁrst day
of follow-up and death was the event studied. Reasons for cen-
soring were loss to follow-up and end of the follow-up period.
RRT and dialysis survival probabilities were adjusted for ﬁxed va-
lues for age (60 years), gender (60% men) and the cause of ESRD
distribution (20% DM, 17% hypertension/renal vascular disease,
15% glomerulonephritis and 48% other causes of ESRD). Trans-
plantation survival probabilities were adjusted for the following
values: age 45 years, 60% men, 10% DM, 8% hypertension/renal
vascular disease, 28% glomerulonephritis and 54% other causes
of ESRD. For the adjusted survival probabilities of the DM sub-
group, the corresponding ﬁxed values were used with the excep-
tion of the cause of ESRD distribution.
Results
For the majority of renal registries contributing data to the ERA-
EDTA Registry, the coverage of the population was 100%, with the
exception of Croatia (80%), Latvia (80%), Serbia (94%), Switzerland
(94%), Spain (95%), Poland (95%), Georgia (96%), Bulgaria (97%),
Czech Republic (98%) and Romania (99%). The total population cov-
ered by the participating registries comprised 650 million people.
The proportion of the European population covered by the ERA-
EDTA Registry in 2013 was 73.6%. A list of the European countries
with available data and thosewithout is provided in the Appendix.
Incidence of RRT in 2013
In 2013, a total of 72 933 patients started RRT for ESRD in all the
registries reporting to the ERA-EDTA Registry, resulting in an
Fig. 2. Unadjusted incidence of RRT pmp at Day 1 in 2013 by cause of ESRD. Data are from renal registries providing individual patient data (left panel) and from renal
registries providing aggregated data (right panel). Data for Bulgaria, the Czech Republic, Lithuania, Slovakia and Switzerland only include dialysis patients. Registries
from Dutch- and French-speaking Belgium, the Spanish regions of Cantabria, Castile and León and Castile-La Mancha and the UK (England, Northern Ireland and
Wales) do not report on patients <20 years of age.
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overall incidence of 112 pmp (Figure 2). For countries/regions
providing individual patient data (left panel), the overall inci-
dence at Day 1 was 135 pmp, while it was 98 pmp for countries
providing aggregated data (right panel). The lowest incidence
rates were found in Montenegro (27 pmp), Ukraine (30 pmp) and
Russia (50 pmp), whereas the highest rates were observed in
Table 1. Unadjusted incidence of RRT pmp for ESRD at Day 91 by established modality in 2013 for countries/regions providing individual patient
data and for countries providing aggregated data
All (pmp) HD (pmp) PD (pmp) Tx (pmp) Other (pmp)
Countries/regions providing individual patient data
Austriaa 132.1 113.0 13.5 5.6 0
Belgium
Dutch-speakingb 168.4 146.2 18.4 3.8 0
French-speakingb 164.9 140.2 19.5 5.3 0
Bosnia and Herzegovina 110.0 106.3 3.7 0 0
Denmark 109.7 66.1 34.4 8.8 0.4
Estonia 59.9 44.0 12.1 3.8 0
Finland 85.7 57.5 27.4 0.7 0
France 145.9 121.3 17.5 6.5 0.6
Greece 194.4 179.9 13.9 0.5 0
Iceland 74.1 30.9 34.0 9.3 0
Norway 96.1 59.5 22.0 14.6 0
Romania 130.5 122.0 6.9 1.5 0
Serbia 136.9 117.0 17.2 2.7 0
Slovenia 114.6 101.5 11.2 1.9 0
Spain
Andalusia 122.2 95.7 21.1 5.4 0
Aragon 125.1 95.9 26.2 3.0 0
Asturiasa 149.2 100.5 45.6 3.1 0
Basque country 114.6 71.8 32.2 10.6 0
Cantabriab 83.2 54.3 22.1 6.8 0
Castile and Leónb 106.5 85.0 18.3 3.2 0
Castile-La Manchab 103.6 76.7 23.5 3.4 0
Cataloniaa 139.3 106.6 20.0 12.8 0
Community of Madrid 117.3 92.4 17.4 7.5 0
Extremaduraa 119.6 102.1 17.5 0.0 0
Galicia 139.8 99.8 31.6 8.3 0
Region of Murcia 103.9 78.8 23.8 1.4 0
Valencia Region 130.0 99.9 28.6 1.6 0
Sweden 104.2 57.5 37.7 9.0 0
The Netherlands 108.4 73.8 17.7 16.8 0
UK
Englanda,b 103.3 71.1 21.1 11.1 0
Northern Irelanda,b 86.4 59.9 16.6 9.8 0
Scotland 91.2 69.3 14.3 7.7 0
Walesa,b 103.7 75.6 19.2 8.9 0
All countries 125.8 99.1 19.1 7.3 0.2
Countries providing aggregated patient data
Albania 59.2 53.6 4.8 0.7 0
Bulgariac 132.3 128.9 3.4 0
Croatia 133.3 123.1 9.0 1.2 0
Cyprus 175.4 145.0 24.6 5.8 0
Czech Republicc 139.3 130.5 8.8 0
Georgia 148.6 139.3 5.8 0.2 3.3
Israel 171.7 146.9 16.3 8.6 0
Latvia 70.6 61.2 8.7 0.6 0
Lithuaniac 106.3 99.6 6.7 0
Montenegro 22.6 14.5 0.0 8.1 0
Portugald 218.9 198.8 19.3 0.9 0
Slovakiac 132.4 128.6 3.9 0
All countries 148.7 136.6 10.2 1.7 0.2
The category HD also includes haemoﬁltration and haemodiaﬁltration. When cells are left empty, the data are unavailable.
HD: haemodialysis, PD: peritoneal dialysis, Tx: kidney transplant.
aThe incidence at Day 91 is based on patients who started RRT in the ﬁrst 9 months of 2013.
bPatients <20 years of age are not reported.
cData include dialysis patients only.
dOnly pre-emptive transplantations (at Day 1) are included.
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Greece (216 pmp) and both parts of Belgium (Dutch-speaking
part: 187 pmp, French-speaking part: 183 pmp). Figure 2 also
shows the contribution of DM as the cause of ESRD to the inci-
dence of RRT. Overall, patients who had DM as the cause of
ESRD comprised 24% of the incident patients (26 pmp). For 48%
of those patients, the type of DM was unknown (12 pmp),
while 12% (3 pmp) had DM type 1 and 40% (10 pmp) had DM
type 2. Among countries/regions whose registries provide
individual patient data, the incidence of RRT for ESRD secondary
to DM ranged between 12 pmp in Iceland and 58 pmp in Greece.
However, in countries with a high proportion of patients with an
unknown or missing cause of ESRD, the proportion of patients
with DM as the cause of ESRD may be underestimated, as DM
may be the cause of ESRD in some of these patients. For this
reason, we also report the incidence of RRT for ESRD due to
unknown or missing causes of ESRD, which varied widely
between 0 pmp in Estonia and 73 pmp in Greece. Countries
providing aggregated data showed a greater difference in the
incidence of RRT secondary to DM, ranging from 5 pmp in
Ukraine to 83 pmp in Israel. In general, countries/regions with a
high overall incidence of RRT also had a high incidence of RRT
for ESRD secondary to DM.
Table 1 shows the unadjusted incidence of RRT pmponDay 91
after the onset of RRT byestablished treatmentmodality (haemo-
dialysis, peritoneal dialysis and kidney transplantation). Overall,
most patients were treated with haemodialysis (99 pmp in renal
registries providing individual patient data and 137 pmp in those
providing aggregated data), whereas the incidence of peritoneal
dialysis was much lower (19 and 10 pmp, respectively). The inci-
dence of kidney transplantation on Day 91 was highest in The
Netherlands (17 pmp) and Norway (15 pmp), whereas it was low-
est in Bosnia and Herzegovina and the Spanish region of Extre-
madura (0 pmp in both cases). Table 2 presents the percentages
of established treatment modalities on Day 91 after the start of
Table 2. Percentages of established RRTmodalities at Day 91, unadjusted, by DM as the cause of ESRD, for countries/regions providing individual
patient data
All DM Other causes of ESRD
Unknown/missing cause
of ESRD
HD PD Tx Other HD PD Tx Other HD PD Tx Other HD PD Tx Other
Austriaa 86 10 4 0 89 9 2 0 84 11 5 0 88 8 4 0
Belgium
Dutch-speakingb 87 11 2 0 92 7 1 0 85 13 3 0 93 6 1 0
French-speakingb 85 12 3 0 90 10 0 0 83 12 4 0 87 9 4 0
Bosnia and Herzegovina 97 3 0 0 97 3 0 0 96 4 0 0 97 3 0 0
Denmark 60 31 8 0 67 30 3 0 60 28 12 0 55 41 4 1
Estonia 73 20 6 0 56 38 6 0 78 16 6 0 0 0 0 0
Finland 67 32 1 0 66 34 0 0 66 33 2 0 75 25 0 0
France 83 12 4 0 88 10 2 0 82 12 5 0 82 14 4 0
Greece 93 7 0 0 91 9 0 0 93 7 0 0 93 6 0 0
Iceland 42 46 13 0 50 25 25 0 44 44 11 0 0 100 0 0
Norway 62 23 15 0 69 17 14 0 60 24 16 0 79 21 0 0
Romania 94 5 1 0 94 5 0 0 93 5 2 0 94 6 0 0
Serbia 85 13 2 0 78 20 1 0 89 9 2 0 82 17 1 0
Slovenia 89 10 2 0 89 11 0 0 85 12 3 0 98 2 0 0
Spain
Andalusia 78 17 4 0 83 15 2 0 74 21 5 0 84 12 5 0
Aragon 77 21 2 0 81 17 2 0 71 26 3 0 87 13 0 0
Asturiasa 67 31 2 0 45 55 0 0 71 28 1 0 90 0 10 0
Basque country 63 28 9 0 72 26 2 0 65 25 10 0 44 42 14 0
Cantabriab 65 27 8 0 77 8 15 0 61 33 6 0 0 0 0 0
Castile and Leónb 80 17 3 0 88 11 1 0 76 21 4 0 80 16 4 0
Castile-La Manchab 74 23 3 0 81 16 4 0 70 26 4 0 78 22 0 0
Cataloniaa 76 14 9 0 82 16 2 0 73 14 13 0 78 14 8 0
Community of Madrid 79 15 6 0 83 15 2 0 74 16 9 0 86 10 4 0
Extremaduraa 85 15 0 0 82 18 0 0 85 15 0 0 90 9 0 1
Galicia 71 23 6 0 78 22 0 0 63 27 10 0 82 14 3 0
Region of Murciaa 76 23 1 0 85 15 0 0 72 26 2 0 76 24 0 0
Valencia Region 77 22 1 0 82 17 1 0 73 25 2 0 82 18 0 0
Sweden 55 36 9 0 60 36 4 0 53 37 10 0 57 34 8 0
The Netherlands 68 16 16 0 82 15 2 0 75 20 6 0 49 11 40 0
UK
Englanda,b 69 20 11 0 76 20 4 0 65 21 14 0 71 20 9 0
Northern Irelanda,b 69 19 11 0 74 23 3 0 69 16 15 0 64 28 8 0
Scotland 76 16 8 0 86 11 3 0 72 17 11 0 78 17 4 0
Walesa,b 73 19 9 0 76 18 6 0 69 20 11 0 80 15 6 0
All countries 77 16 6 0 82 15 2 0 76 17 7 0 77 15 7 0
The category HD also includes haemoﬁltration and haemodiaﬁltration. Categories may not add up because of missing values or rounding off. Percentages are row
percentages. When cells are left empty, the data are unavailable.
HD: haemodialysis, PD: peritoneal dialysis, Tx: kidney transplant.
aThe incidence at Day 91 is based on patients who started RRT in the ﬁrst 9 months of 2013.
bPatients <20 years of age are not reported.
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Fig. 3. Unadjusted incidence of RRT pmp at Day 1 by cause of ESRD for the USA [4] and Europe. Data for Europe were based on those renal registries that had individual
patient data available from 2004, including Austria, Belgium (Dutch-speaking and French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia,
Aragon, Asturias, Basque country, Cantabria, Castile and León, Castile-La Mancha, Catalonia and Valencia Region), Sweden, The Netherlands and UK (all countries).
Fig. 4.Unadjusted prevalence of RRT pmpon 31December 2013 by cause of ESRD. Data are from renal registries providing individual patient data (left panel) and from renal
registries providing aggregated data (right panel). Data for Israel, Slovakia and Switzerland only include dialysis patients. For Romania, the overall prevalence of RRT is
underestimated by ∼3% due to an estimated 30% underreporting of patients living on a functioning graft. Registries from Dutch- and French-speaking Belgium, the
Spanish regions of Cantabria, Castile and León and Castile-La Mancha and the UK (England, Northern Ireland and Wales) do not report on patients <20 years of age.
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Table 3. Unadjusted prevalence of RRT pmp for ESRD on 31 December 2013 by treatment modality for countries/regions providing individual
patient data and for countries providing aggregated data
All (pmp) HD (pmp) PD (pmp) Tx (pmp) Other (pmp)
Countries/regions providing individual patient data
Austria 1053.7 471.3 49.8 532.4 0.2
Belgium
Dutch-speakinga 1223.1 648.7 56.8 517.6 0
French-speakinga 1269.9 677.6 57.5 530.6 4.2
Bosnia and Herzegovina 746.9 666.5 24.2 56.2 0
Denmark 876.9 354.1 95.0 424.6 3.2
Estonia 572.1 192.7 33.4 346.0 0
Finland 825.9 269.2 65.8 490.9 0
France 1175.1 601.1 44.4 522.1 7.5
Greece 1172.1 871.8 61.3 239.0 0
Iceland 685.7 148.3 77.2 460.2 0
Norway 900.5 212.8 39.0 648.7 0
Romaniab 816.9 676.7 75.8 64.1 0.3
Serbia 839.1 648.2 69.9 120.4 0.6
Slovenia 1008.3 654.9 25.2 328.2 0
Spain
Andalusia 1107.7 493.5 46.4 567.9 0
Aragon 1131.2 416.5 53.2 661.5 0
Asturias 1131.3 402.7 105.8 622.8 0
Basque country 1175.4 373.8 90.2 711.3 0
Cantabriaa 998.5 336.2 59.4 602.9 0
Castile and Leóna 1123.6 484.2 73.8 565.6 0
Castile-La Manchaa 1025.5 390.0 59.0 575.6 1.0
Catalonia 1262.2 532.2 53.4 676.6 0
Community of Madrid 999.3 388.7 54.3 556.2 0
Extremadura 1081.5 531.7 66.1 482.8 0.9
Galicia 1220.9 537.6 101.3 581.9 0
Region of Murcia 1200.4 609.4 63.9 527.2 0
Valencia Region 1232.5 651.4 77.4 502.0 1.8
Sweden 939.5 313.2 86.8 539.5 0.1
The Netherlands 945.4 332.0 55.2 558.2 0
UK
Englanda 890.4 372.9 59.0 458.5 0
Northern Irelanda 846.0 354.2 44.3 447.6 0
Scotland 866.0 350.4 43.4 471.9 0.4
Walesa 886.0 348.1 57.4 480.5 0
All countries 1019.8 501.0 57.5 459.3 2.0
Countries providing aggregated patient data
Albania 340.5 257.1 18.0 65.4 0
Bulgaria 540.9 449.4 22.3 69.3 0
Croatia 799.5 583.3 37.1 159.9 19.3
Czech Republic 1033.5 562.3 50.3 420.9 0
Georgia 385.2 324.1 20.8 38.5 1.9
Israelc 734.7 692.1 42.4 0.1
Latvia 600.3 221.8 53.7 324.8 0
Lithuania 719.0 475.4 15.8 227.8 0
Montenegro 304.8 133.9 4.8 166.1 0
Poland 822.4 513.4 27.9 281.1 0
Portugal 1749.3 1046.7 69.8 632.8 0
Russia 241.4 179.8 13.8 47.8 0
Slovakiac 609.0 592.9 16.1
Spain (18 of 19 regions) 1125.8 482.1 62.1 579.9 1.8
Switzerlandc 381.6 349.5 32.0 0.1
Turkey 870.2 687.1 59.2 123.9 0
Ukraine 159.0 117.6 21.3 20.1 0
All countries 589.6 392.4 33.4 163.3 0.4
The category HD also includes haemoﬁltration and haemodiaﬁltration. When cells are left empty, the data are unavailable.
HD: haemodialysis, PD: peritoneal dialysis, Tx: kidney transplant.
aPatients <20 years of age are not reported.
bThe overall prevalence of RRT is underestimated by ∼3% due to an estimated 30% underreporting of patients living with a functioning graft.
cData include dialysis patients only.
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RRT for all patients, for patients with DM, for patients with other
causes of ESRD and for patients with an unknown cause of ESRD.
Patients with DMweremore often treated with any type of dialy-
sis on Day 91 after the start of RRT than patients with other
causes of ESRD (98 versus 93%), while they were less often trans-
planted (2 versus 7%).
Trends in the incidence of RRT over time in the USA and
Europe
Figure 3 shows the trend in the incidence of RRT over the last 10
years, by cause of ESRD, in both Europe and the USA [data ex-
tracted from the US Renal Data System (USRDS) Annual Report
[4]]. When compared with the USA, the incidence of patients
starting RRT for ESRD secondary to DM is almost ﬁve times
lower in Europe and the incidence of RRT for ESRD due to other
causes of ESRD is at least two times lower. Joinpoint regression
analyses revealed that in Europe, the incidence of patients start-
ing RRT for ESRD secondary to DMdecreased from 2007, although
this was not statistically signiﬁcant {2004–7: APC 1.9 [95%
conﬁdence interval (CI) −1.1–+5.1], 2007–13: APC −0.9 [95% CI
−1.9–0.2]}. In the USA, the reported incidence of RRT for ESRD sec-
ondary to DM remained stable during the last decade [APC 0.2
(95% CI −0.2–0.5)].
Prevalence of RRT on 31 December 2013
Figure 4 shows the unadjusted prevalence of RRT pmp on 31
December 2013, by cause of ESRD. Overall, 477 186 patients
were receiving RRT on 31 December 2013, resulting in an
overall prevalence of 738 pmp The prevalence was highest in
Portugal (1749 pmp), French-speaking Belgium (1270 pmp) and
the Spanish region of Catalonia (1262 pmp), whereas it was low-
est in Ukraine (159 pmp), Russia (241 pmp) and Montenegro
Table 4. Percentages of RRT modalities among prevalent patients on 31 December 2013, unadjusted, by DM as the cause of ESRD for countries/
regions providing individual patient data
All DM Other causes of ESRD
Unknown/missing cause
of ESRD
HD PD Tx Other HD PD Tx Other HD PD Tx Other HD PD Tx Other
Austria 45 5 51 0 60 4 36 0 40 5 55 0 45 5 50 0
Belgium
Dutch-speakinga 53 5 42 0 71 4 25 0 48 5 47 0 57 2 41 0
French-speakinga 53 5 42 0 71 5 23 0 50 4 45 0 44 5 51 0
Bosnia and Herzegovina 89 3 8 0 92 5 3 0 89 3 8 0 87 2 11 0
Denmark 40 11 48 0 54 13 33 0 36 9 55 0 44 15 41 0
Estonia 34 6 60 0 26 10 64 0 36 5 60 0 0 0 0 0
Finland 33 8 59 0 40 10 50 0 26 6 67 0 56 12 32 0
France 51 4 44 1 73 5 22 0 47 3 49 1 51 5 43 1
Greece 74 5 20 0 89 7 4 0 68 5 27 0 77 5 19 0
Iceland 22 11 67 0 29 13 58 0 20 10 70 0 29 29 43 0
Norway 24 4 72 0 34 4 63 0 22 4 74 0 42 5 54 0
Romaniab 83 9 8 0 86 11 3 0 81 9 9 0 84 9 7 0
Serbia 77 8 14 0 77 16 7 0 78 7 15 0 73 9 17 0
Slovenia 65 3 33 0 86 3 11 0 59 2 39 0 70 2 27 0
Spain
Andalusia 45 4 51 0 63 6 31 0 39 4 57 0 50 3 47 0
Aragon 37 5 58 0 57 6 37 0 36 4 60 0 24 4 72 0
Asturias 36 9 55 0 46 18 36 0 32 8 60 0 39 6 55 0
Basque country 32 8 61 0 56 12 32 0 27 7 67 0 38 11 52 0
Cantabriaa 34 6 60 0 50 6 44 0 31 6 63 0 36 0 64 0
Castile and Leóna 43 7 50 0 60 7 32 0 45 8 47 0 29 3 68 0
Castile-La Manchaa 38 6 56 0 57 7 35 0 33 6 61 0 39 4 57 0
Catalonia 42 4 54 0 63 6 31 0 34 3 62 0 51 5 43 0
Community of Madrid 39 5 56 0 57 7 36 0 33 6 61 0 43 3 54 0
Extremadura 49 6 45 0 76 7 17 0 43 7 50 0 46 4 50 0
Galicia 44 8 48 0 63 11 26 0 37 8 56 0 49 9 42 0
Region of Murcia 51 5 44 0 71 6 23 0 46 6 48 0 52 4 44 0
Valencia Region 53 6 41 0 71 7 22 0 47 6 46 0 59 6 35 0
Sweden 33 9 57 0 45 12 43 0 29 8 63 0 43 12 45 0
The Netherlands 35 6 59 0 55 7 38 0 33 6 62 0 32 5 63 0
UK
Englanda 42 7 51 0 59 9 32 0 37 6 58 0 45 8 47 0
Northern Irelanda 42 5 53 0 66 6 28 0 36 5 59 0 46 9 45 0
Scotland 40 5 54 0 59 6 35 0 35 5 60 0 48 5 47 0
Walesa 39 6 54 0 55 7 39 0 34 7 60 0 46 5 49 0
All countries 49 6 45 0 66 8 27 0 45 5 50 0 51 6 41 0
The category HD also includes haemoﬁltration and haemodiaﬁltration. When cells are left empty, the data are unavailable.
HD: haemodialysis, PD: peritoneal dialysis, Tx: kidney transplant.
aPatients <20 years of age are not reported.
bThe overall prevalence of RRT is underestimated by ∼3% due to an estimated 30% underreporting of patients living with a functioning graft.
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(305 pmp). Patients with DM as the cause of ESRD comprised 17%
of the prevalent patients (122 pmp). For 54% of these patients, the
type of DM was unknown (66 pmp), while 14% (18 pmp) had DM
type 1 and 31% (38 pmp) had DM type 2. In countries/regions
with registries providing individual patient data, the overall
prevalence of RRT for ESRD secondary to DM was 159 pmp, ran-
ging between 74 pmp in Iceland and 219 pmp in Greece. Tables 3
and 4 present the prevalence by treatment modality (haemodi-
alysis, peritoneal dialysis and kidney transplantation) on 31 De-
cember 2013 (pmp and as percentage). In countries/regions
with registries providing individual patient data, most prevalent
patients were receiving haemodialysis, closely followed by those
with a functioning graft. In countries with registries providing ag-
gregated data, the great majority of the patients were receiving
haemodialysis. Table 4 shows that in case of patients with DM
as the cause of ESRD, only four registries reported ≥50% of pa-
tients living with a functioning graft. In contrast, for other causes
of ESRD, the vast majority of the registries reported that more
than half of the patients had a functioning graft.
Kidney transplants performed in 2013
Figure 5 shows the kidney transplant rate in 2013 for countries/re-
gions whose registries provide individual patient data and for
countries whose registries provide aggregated patient data, by
donor type. Overall, 19 426 kidney transplantations were per-
formed (30 pmp), of which 6002 (9 pmp) transplants came from
living donors, 13 207 (20 pmp) from deceased donors and 217
(0.3 pmp) from an unknown donor source. The three Spanish
regions—Cantabria (104 pmp), Basque country (75 pmp) and
Catalonia (71 pmp)—had the highest kidney transplant rates,
while Ukraine (3 pmp), Albania (3 pmp) and Russia (7 pmp)
showed the lowest rates. The highest living donor kidney trans-
plant rates were found in The Netherlands (31 pmp), Turkey
(31 pmp) and Cyprus (27 pmp).
Patient survival
Survival analyses included data from22 registries in 11 countries,
which provided individual patient data for the period of 2004–11.
Fig. 5. Kidney transplants pmp performed in 2013, unadjusted. Data are from renal registries providing individual patient data (left panel) and aggregated data (right
panel). For Slovakia, data were obtained from the Slovak Centre of Organ Transplantation, and for Spain (18 of 19 regions), from the Organización Nacional de
Transplantes. For Romania, the kidney transplantation activity reﬂects 70% of the total kidney transplantation activity in the country due to an underreporting of pre-
emptive kidney transplantations. Registries fromDutch- and French-speaking Belgium, the Spanish regions of Cantabria, Castile and León and Castile-LaMancha and the
UK (England, Northern Ireland and Wales) do not report on patients <20 years of age.
466 | A. Kramer et al.
C
L
IN
IC
A
L
K
ID
N
E
Y
JO
U
R
N
A
L
 at M
edical and H
ealth Inform
ation Center on A
ugust 25, 2016
http://ckj.oxfordjournals.org/
D
ow
nloaded from
 
Table 5 shows the unadjusted and adjusted survival probabilities
for patients starting RRT or dialysis or receiving their ﬁrst kidney
transplant between 2004 and 2008. In order to present more re-
cent survival data, 1- and 2-year survival probabilities are also
presented, for patients starting RRT/dialysis or receiving their
ﬁrst kidney transplant between 2007 and 2011. The survival of pa-
tients with DM as the cause of ESRD was worse when compared
with the total group of patients starting RRT, dialysis or receiving
a kidney transplant. Two-year survival probabilities were higher
for patients starting RRT, dialysis or receiving a kidney transplant
between 2007 and 2011 than between 2004 and 2008.
Paediatric patients
For children, we performed a separate analysis of the incidence
and prevalence by age group using data from 25 national or re-
gional renal registries from 16 countries that provided individual
paediatric data. In 2012–13, 686 children [7.5 per million age-re-
lated population (pmarp)] started RRT. Of these children, 135 (6.0
pmarp) were <5 years of age at the onset of RRT, 96 (4.2 pmarp)
were ages 5–9 years, 175 (7.7 pmarp) were ages 10–14 years and
280 (12.1 pmarp) were ages 15–19 years. On 31 December 2013,
2529 (55.3 pmarp) childrenwere receiving RRT, ofwhom203 (18.0
pmarp) were <5 years of age, 423 (36.6 pmarp) were ages 5–9
years, 686 (60.2 pmarp) were ages 10–14 years and 1217 (105.9
pmarp) were ages 15–19 years.
Amore detailed overview of the paediatric RRT data in Europe
can be found at the ESPN/ERA-EDTA Registry website (http://
www.espn-reg.org).
Discussion
This summary of the 2013 ERA-EDTA Registry Annual Report in-
cludes data from 49 national and regional renal registries in 34
countries in Europe and bordering the Mediterranean Sea, with a
special focus on patients receiving RRT for ESRD secondary to DM.
Both the overall incidence of RRT for ESRD and the incidence
of RRT for ESRD secondary to DMwere substantially lower in Eur-
ope than in the USA [4]. However, even in Europe and among
countries bordering the Mediterranean Sea, there were notable
differences in the incidence of RRT for ESRD secondary to DM.
This variation may be explained in part by differences in the
prevalence of DM within the general population [5], differences
in preventivemeasures, such as lifestyle advice and the use of re-
noprotective medication, and differences in macroeconomic fac-
tors and nephrology services [6]. It should be noted that this
variation may also be inﬂuenced by discrepancies in the propor-
tion of patients coded with amissing or unknown cause of ESRD.
Table 5. One-, 2- and 5-year unadjusted and adjusted patient survival probabilities (in %) with 95% conﬁdence interval for all patients and for
patients with DM as the cause of ESRD
2004–8 period 2007–11 period
1 year 2 year 5 year 1 year 2 year
Patient survival on RRT
Unadjusted
All 82.1 (81.9–82.3) 71.2 (71.0–71.4) 48.3 (48.2–48.5) 83.5 (83.3–83.7) 73.1 (72.9–73.3)
DM 82.3 (81.8–82.7) 68.8 (68.4–69.2) 40.2 (39.9–40.4) 83.9 (83.5–84.3) 71.1 (70.7–71.5)
Adjusteda
All 89.2 (89.0–89.3) 81.4 (81.1–81.7) 60.9 (60.5–61.3) 90.0 (89.8–90.2) 82.7 (82.5–83.0)
DM 87.8 (87.4–88.1) 77.3 (76.8–77.8) 50.6 (49.9–51.2) 89.0 (88.7–89.4) 79.4 (78.9–79.9)
Patient survival on dialysis (with kidney transplantation as competing event)
Unadjusted
All 81.6 (81.4–81.8) 70.5 (70.3–70.8) 48.1 (47.9–48.4) 82.8 (82.6–83.0) 72.1 (71.9–72.3)
DM 82.0 (81.6–82.4) 68.6 (68.2–69.0) 40.6 (40.1–41.1) 83.5 (83.2–83.9) 70.6 (70.1–71.1)
Adjusteda
All 89.4 (89.3–89.6) 81.9 (81.7–82.1) 62.4 (62.2–62.8) 89.9 (90.0–89.8) 82.6 (82.8–82.4)
DM 87.3 (87.1–87.5) 78.5 (78.2–78.8) 56.6 (56.2–57.0) 88.5 (88.6–88.3) 80.2 (80.5–80.0)
Patient survival after ﬁrst kidney transplantation (deceased donor)
Unadjusted
All 95.7 (95.4–96.0) 93.7 (93.4–94.1) 87.1 (86.7–87.5) 96.0 (95.7–96.2) 94.0 (93.6–94.3)
DM 93.9 (93.0–94.7) 91.3 (90.3–92.2) 81.6 (80.3–82.7) 94.8 (94.0–95.4) 92.2 (91.3–93.0)
Adjusteda
All 97.4 (97.2–97.6) 96.1 (95.9–96.4) 91.8 (91.4–92.2) 97.6 (97.4–97.8) 96.4 (96.1–96.6)
DM 95.8 (95.1–96.4) 93.8 (93.1–94.6) 86.5 (85.4–87.7) 96.5 (95.9–97.0) 94.7 (94.0–95.4)
Patient survival after ﬁrst kidney transplantation (living donor)
Unadjusted
All 98.3 (98.0–98.6) 97.4 (97.0–97.8) 94.3 (93.7–94.8) 98.6 (98.3–98.8) 97.6 (97.3–97.9)
DM 96.3 (94.2–97.6) 93.4 (90.9–95.2) 85.3 (82.3–87.8) 96.8 (95.3–97.9) 94.9 (93.0–96.2)
Adjusteda
All 98.7 (98.4–99.0) 98.1 (97.7–98.4) 95.6 (95.0–96.1) 99.1 (98.9–99.3) 98.4 (98.2–98.7)
DM 97.5 (96.4–98.7) 95.6 (94.0–97.2) 89.8 (87.5–92.3) 98.1 (97.3–98.9) 96.9 (95.8–98.0)
Based on data from Austria, Belgium (Dutch-speaking and French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia, Aragon, Asturias, Basque
country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura and Valencia Region), Sweden, The Netherlands and UK (all countries).
aAdjusted survival probabilities were adjusted for age, gender and cause of ESRD. For the adjusted survival probabilities of the DM subgroup, only age and gender were
taken into account.
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Nevertheless, in view of the ongoing epidemic of DM in Western
societies [5], it is remarkable that both in Europe and in the USA,
the rise in the incidence of RRT for ESRD secondary to DM ap-
pears to have subsided.
Although patients receiving RRT for ESRD secondary to DM
were less likely to receive a kidney transplant and had worse
survival compared with the overall group, their survival seems
to be improving with time.
In conclusion, we have shown encouraging results for pa-
tients receiving RRT for ESRD secondary to DM. This suggests
that advances in health care have been effective with regard to
the prevention and management of ESRD secondary to DM.
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Appendix
Coverage of the European population by the
ERA-EDTA registry
European countries supplying data to the ERA-EDTA Registry
in 2013: Albania, Austria, Belgium, Bosnia and Herzegovina,
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Georgia, Greece, Iceland, Latvia, Lithuania,
Montenegro, the Netherlands, Norway, Poland, Portugal,
Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden,
Switzerland, Turkey, Ukraine and the UK.
European countries not supplying data to the ERA-EDTA Registry
in 2013: Andorra, Armenia, Azerbaijan, Belarus, former Yugoslav
Republic of Macedonia, Germany, Hungary, Ireland, Italy, Kosovo
(underUnitedNations SecurityCouncil Resolution1244/99), Liech-
tenstein, Luxembourg, Malta, Moldova, Monaco and San Marino.
The coverage of the European population by the ERA-EDTARegis-
try in 2013 was 73.6%. For this calculation, only the proportions
of the population residing in the European part of Russia and
Turkey were considered.
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